TY - JOUR
T1 - Long term survival in multiple myeloma
T2 - a single institution experience in underprivileged circumstances
AU - Bojalil-Alvarez, Lorena
AU - Gertz, Morie A.
AU - Garcia-Villaseñor, Elizabeth
AU - Fernández-Gutiérrez, José Antonio
AU - Reyes-Cisneros, Oscar Alfonso
AU - Murrieta-Alvarez, Iván
AU - Cantero-Fortiz, Yahveth
AU - Ruiz-Delgado, Guillermo J.
AU - Ruiz-Argüelles, Guillermo J.
N1 - Publisher Copyright:
© 2021 Informa UK Limited, trading as Taylor & Francis Group.
PY - 2022
Y1 - 2022
N2 - There is data suggesting that the clinical behavior of multiple myeloma (MM) may be different in Latin Americans than in Caucasian or African-Americans, consistent with a less aggressive course of MM in Latinos. We analyzed the overall survival (OS) of 139 persons with MM in a single institution in México, as well the variables which were associated with long-term OS. Of all patients, the median OS was 11 years whereas the 5-year and 10-year OS were 75% and 55% respectively. The analysis of variables showed that the variable related with five-year survival was having hematopoietic stem cell transplantation (HSCT), whereas the variables related with 10-year survival were HSCT, age at diagnosis (patients younger than 50 survived longer), light chain type (kappa survived longer) and ISS stage (stage I patients survived longer). The only variable associated with both 5 and 10-year survival was HSCT. A plateau in the OS was reached after 10 years, both in grafted and non-grafted patients. We have confirmed the critical role of HSCT in the prognosis of persons with MM, independent of the induction treatment or the maintenance post-transplant, and we have identified a better prognosis in this cohort, as compared with African-Americans or Caucasians, since the proportion of long-term survivors in our group is seemingly better than those in other populations.
AB - There is data suggesting that the clinical behavior of multiple myeloma (MM) may be different in Latin Americans than in Caucasian or African-Americans, consistent with a less aggressive course of MM in Latinos. We analyzed the overall survival (OS) of 139 persons with MM in a single institution in México, as well the variables which were associated with long-term OS. Of all patients, the median OS was 11 years whereas the 5-year and 10-year OS were 75% and 55% respectively. The analysis of variables showed that the variable related with five-year survival was having hematopoietic stem cell transplantation (HSCT), whereas the variables related with 10-year survival were HSCT, age at diagnosis (patients younger than 50 survived longer), light chain type (kappa survived longer) and ISS stage (stage I patients survived longer). The only variable associated with both 5 and 10-year survival was HSCT. A plateau in the OS was reached after 10 years, both in grafted and non-grafted patients. We have confirmed the critical role of HSCT in the prognosis of persons with MM, independent of the induction treatment or the maintenance post-transplant, and we have identified a better prognosis in this cohort, as compared with African-Americans or Caucasians, since the proportion of long-term survivors in our group is seemingly better than those in other populations.
KW - Myeloma
KW - survival
KW - treatment
UR - http://www.scopus.com/inward/record.url?scp=85121500761&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85121500761&partnerID=8YFLogxK
U2 - 10.1080/10428194.2021.2012665
DO - 10.1080/10428194.2021.2012665
M3 - Article
C2 - 34898338
AN - SCOPUS:85121500761
SN - 1042-8194
VL - 63
SP - 1236
EP - 1241
JO - Leukemia and Lymphoma
JF - Leukemia and Lymphoma
IS - 5
ER -